Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

PD-1/PD-L1

PD-1 (CD279) is a type I transmembrane protein composed of 288 amino acid residues, belonging to the CD28 family. It is widely expressed on a variety of immune cells, such as activated T cells, B cells, NK cells and DC cells. PD-L1 (CD274) is a ligand of PD-1, that is, a protein that can pair and bind to PD-1. It consists of 290 amino acid residues, mainly including short cytoplasmic tail region, transmembrane region, and IgV and IGC-like extracellular domains. PD-L1 is expressed in tumor cells and antigen presenting cells (APC). PD-1 and its ligand PD-L1 pathway control the induction and maintenance of immune tolerance in the tumor microenvironment. PD-1/PD-L1 activity is responsible for the activation, proliferation and cytotoxic secretion of T cells in cancer, thereby reducing the degenerate anti-tumor immune response.

TargetMol
Anti-Mouse PD-1 Antibody (RMP1-14)
T78269
RMP1-14 is an IgG-like immunoglobulin antibody against mouse PD-1 that can block PD-1 PD-L1 signaling; its isotype control antibody is Mouse IgG2a kappa, Isotype Control.
  • $78
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Pembrolizumab
T99081374853-91-4
Pembrolizumab (MK-3475) is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that impairs the ability of HER2 to bind to other members of the HER family.
  • $218
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Atezolizumab
T99021380723-44-3
Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.
  • $229
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Nivolumab
T9907946414-94-4
Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity and is used in the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and others.
  • $182
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Avelumab
T99031537032-82-8
Avelumab, a fully human IgG1 anti-PD-L1 monoclonal antibody, exhibits potential antibody-dependent cell-mediated cytotoxicity.
  • $289
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Anti-Mouse PD-L1 Antibody (10F.9G2)
T78270
Anti-Mouse PD-L1 Antibody (10F.9G2) is an IgG-class antibody against mouse PD-L1.
  • $70
In Stock
Size
QTY
AUNP-12 acetate
TP1076L
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition to immune activation and antitumor activity.
  • $116
In Stock
Size
QTY
Durvalumab
T111261428935-60-7
Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and 0.04 nM, respectively. Durvalumab is often used in combination with platinum-based compounds for the treatment of non-small cell lung cancer and advanced hepatocellular carcinoma cells.
  • $228
In Stock
Size
QTY
ARB-272572
T399142368182-63-0In house
ARB-272572 is a potent inhibitor of programmed cell death ligand 1 (PD-L1) signaling that induces PD-L1 homodimer interactions and produces immunostimulatory activity in human primary cells.
  • $139
In Stock
Size
QTY
BMS-202
T31461675203-84-5
BMS-202 (PD1-PDL1 inhibitor 2) is an inhibitor of the PD-1 (Programmed death- 1) PD-Ll (Programmed death-ligand 1) protein protein interaction.
  • $57
In Stock
Size
QTY
TargetMol | Inhibitor Hot
BMS-1166
T56971818314-88-3
BMS-1166 is a potent inhibitor of the PD-1 PD-L1 interaction.
  • $68
In Stock
Size
QTY
PD-1/PD-L1-IN-10
T96162487550-41-2
PD-1 PD-L1-IN-10 is an orally available PD-1 PD-L1 inhibitor (IC50 value of 2.7 nM) that shows anti-tumor activity.
  • $44
In Stock
Size
QTY
TargetMol | Inhibitor Sale
BMS-1
T36551675201-83-8
BMS-1 (PD-1 PD-L1 inhibitor 1) is an inhibitor of the PD1-PD-L1 protein-protein interaction. It also acts as an immunomodulator. Programmed death ligand 1 (PD-L1) is a protein in humans that is encoded by the CD274 gene and the upregulation of PD-L1 allows Ys to evade the host immune system. High tumor expression of PD-L1 was associated with increased tumor aggressiveness and a 4.5-fold increased risk of death.
  • $48
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Camrelizumab
T375351798286-48-2
Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity directed against PD-1, binding PD-1 with an affinity of up to 3 nM and inhibiting PD-1 PD-L1 with an IC50 of 0.70 nM. Camrelizumab exhibits anti-tumor activity and is well tolerated in cancers, including NSC-LC, ESCC, Hodgkin's lymphoma, and advanced HCC.
  • $163
In Stock
Size
QTY
BMS-8
T268591675201-90-7
BMS-8 is a novel inhibitor of the PD-1 PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.
  • $33
In Stock
Size
QTY
INCB086550
T368992230911-59-6
INCB086550 (PD-1 PD-L1-IN-8) (example 24) is a PD-1 PD-L1 inhibitor, with an IC50 <= 10 nM.
  • $148
In Stock
Size
QTY
PD-1/PD-L1-IN-9
T96512628506-54-5In house
PD-1 PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1 PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model.
  • $55
In Stock
Size
QTY
BMS-1001 hydrochloride
T105652113650-04-5
BMS-1001 hydrochloride is an orally active inhibitor of human PD-1 PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. BMS-1001 is capable of alleviating the PD-1 PD-L1 immune checkpoint-mediated exhaustion of Jurkat T-lymphocytes.
  • $51
In Stock
Size
QTY
BMS-1001
T84702113650-03-4
BMS-1001 is a potent inhibitor of PD-1 PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).
  • $56
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Tomivosertib
T34681849590-01-7
Tomivosertib (eFT508) is a potent and highly selective MNK1 and MNK2 inhibitor with an IC50 value of 1-2 nM.
  • $42
In Stock
Size
QTY
PD-1-IN-22
T123792349372-98-9In house
PD-1-IN-22 is a potent inhibitor of the programmed cell death-1 (PD-1) programmed cell death-ligand 1 (PD-L1) interaction, with an IC50 of 92.3 nM.
  • $117
In Stock
Size
QTY
N-deacetylated BMS-202
T121432310135-18-1
N-deacetylated BMS-202 is an inhibitor of PD-1 PD-L1 interactions and has potential anticancer activity for cancer research.
  • $62
In Stock
Size
QTY
PROTAC PD-1/PD-L1 degrader-1
T401122447066-37-5
PROTAC PD-1 PD-L1 degrader-1, a Cereblon E3 ligand-based compound, is a PD-1 PD-L1 PROTAC that effectively inhibits the PD-1 PD-L1 interaction with an IC50 of 39.2 nM. It restores the suppressed immune response in a co-culture model of Hep3B OS-8 hPD-L1 cells and CD3 T cells and moderately decreases PD-L1 protein levels through a lysosome-dependent mechanism.
  • $253
In Stock
Size
QTY
Tislelizumab
T767031858168-59-8
Tislelizumab (BGB-A317) is an IgG4 class monoclonal antibody targeting human programmed death receptor-1 (PD-1) with antitumor activity that inhibits the binding of Fcγ receptor to macrophages and can be used to study advanced squamous non-small cell lung cancer.
  • $98
In Stock
Size
QTY